Relmapirazin

DB19130InvestigationalSmall molecule

Relmapirazin is under investigation in clinical trial NCT05425719 (Pharmacokinetics and Safety of MB-102 (Relmapirazin) and the Medibeacon Transdermal GFR Measurement System in Evaluation of Kidney Function in Normal and Renal...

Formula / weight: C₁₂H₁₆N₆O₈ · 372.294 g/mol (avg)
Also known as: D-serine, n,n'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis- · Lumitrace · N,n'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis(d-serine)
Code names: MB-102

Resolves to

Compound

UNIIQ3UQB8PQ6HCAS1313706-17-0ChEMBLCHEMBL1949708ChEBI750303PubChem53389120

Structure

InChIKeyXHNJXRDGTITISI-QWWZWVQMSA-NSMILESNC1=NC(C(=O)N[C@H](CO)C(O)=O)=C(N)N=C1C(=O)N[C@H](CO)C(O)=O

Targets

P26951IL3RA

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Relmapirazin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account